Placeholder

Chlormethine Hydrochloride

  • # LGM Pharma is a Chlormethine Hydrochloride CAS# 55-86-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Chlormethine Hydrochloride
  • CAS #: 55-86-7
  • Mode of Action:

    Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Mechlorethamine is cell cycle phase-nonspecific.

  • Pharmacodynamics:

    Mechlorethamine also known as mustine, nitrogen mustard, and HN2, is the prototype anticancer chemotherapeutic drug. Successful clinical use of mechlorethamine gave birth to the field of anticancer chemotherapy. The drug is an analogue of mustard gas and was derived from toxic gas warfare research. It belongs to the group of nitrogen mustard alkylating agents. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

  • Metabolism:

    Undergoes rapid chemical transformation and combines with water or reactive compounds of cells, so that the drug is no longer present in active form a few minutes after administration.

  • Toxicity:

    Symptoms of overexposure include severe leukopenia, anemia, thrombocytopenia, and a hemorrhagic diathesis with subsequent delayed bleeding may develop. Death may follow. The most common adverse reactions (≥5%) of the topical formulation are dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, and hyperpigmentation. The oral LD50 for a rat is 10 mg/kg.

  • IUPAC: Chlormethine hydrochloride Diethylamine, 2, 2'-dichloro-N-methyl, hydrochloride Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl-, hydrochloride Nitrogen mustard hydrochloride Stickstofflost-ebewe
  • ATC: L01AA05
  • PubChem: 4033
  • DrugBank: DB00888 (APRD00249)
  • Formula: C5-H11-Cl2-N.Cl-H
  • Molecular Mass: 192.5158
  • Synonyms: 1,5-Dichloro-3-methyl-3-azapentane hydrochloride, 2,2'-Dichloro-N-methyldiethylamine hydrochloride, 2-Chloro-N-(2-chloroethyl)-N-methylethanamine hydrochlroide, AI3-16195, Azotoyperite, beta,beta'-Dichlorodiethyl-N-methylamine hydrochloride, Bis(2-chloroethyl)methylamine hydrochloride, C 6866, Caryolysine, CCRIS 448, Chloramin, Chlorethamine, Chlormethine hydrochloride, Chlormethinum, Dema, Di(2-chloroethyl)methylamine hydrochloride, Dichloren, Dichloromethyldiethylamine hydrochloride, Dimitan, EINECS 200-246-0, Embichin, Embikhine, Embiquine, Erasol, Erasol-Ido, HN2 hydrochloride, HSDB 7176, Kloramin (VAN), Mechlorethamine chloridrate, Mechlorethamine HCl, Mechlorethamine hydrochloride, Methyl-bis(beta-chloroethyl)amine hydrochloride, Methylbis(2-chloroethyl)amine hydrochloride, Methyldi(2-chloroethyl)amine hydrochloride, Methyldi(beta-chloroethyl)amine hydrochloride, Mitoxine, Mustargen, Mustin hydrochloride, Mustine hydrochloride, N,N-Bis(2-chloraethyl)methylamin-hydrochlorid, N,N-Bis(2-chloraethyl)methylamin-hydrochlorid [German], N,N-Bis(2-chloroethyl)methylamine hydrochloride, N-Methyl-2,2'-dichlorodiethylamine hydrochloride, N-Methyl-bis-beta-chlorethylamine hydrochloride, N-Methyl-di-2-chloroethylamine hydrochloride, N-Methylbis(2-chloroethyl)amine hydrochloride, N-Mustard, N-Mustard [German], NCI-C56382, Nitol, Nitol takeda, Nitrogen mustard (HN-2), hydrochloride, Nitrogen mustard hydrochloride, Nitrogranulogen hydrochloride, NSC 762, Pliva, SK 101, Stickstofflost, UNII-L0MR697HHI, Zagreb
  • SMILES: CN(CCCl)CCCl.Cl
  • AHFS Code: 10:00.00, 84:92
  • InChl: 1S/C5H11Cl2N.ClH/c1-8(4-2-6)5-3-7;/h2-5H2,1H3;1H
  • General Reference:

    1. FDA label

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service